Clinical and Experimental Reproductive Medicine

  • 제38권4호
  • /
  • Pages.222-227
  • /
  • 2011
  • /
  • 2233-8233(pISSN)
  • /
  • 2233-8241(eISSN)
대한생식의학회 (The Korean Society for Reproductive Medicine)
권호 표지
DOI QR코드

DOI QR Code

Serum anti-M$\ddot{u}$llerian hormone is a better predictor of ovarian response than FSH and age in IVF patients with endometriosis

  • Yoo, Ji-Hee (Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Cheil General Hospital and Women's Healthcare Center, Kwandong University College of Medicine) ;
  • Cha, Sun-Hwa (Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Cheil General Hospital and Women's Healthcare Center, Kwandong University College of Medicine) ;
  • Park, Chan-Woo (Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Cheil General Hospital and Women's Healthcare Center, Kwandong University College of Medicine) ;
  • Kim, Jin-Young (Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Cheil General Hospital and Women's Healthcare Center, Kwandong University College of Medicine) ;
  • Yang, Kwang-Moon (Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Cheil General Hospital and Women's Healthcare Center, Kwandong University College of Medicine) ;
  • Song, In-Ok (Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Cheil General Hospital and Women's Healthcare Center, Kwandong University College of Medicine) ;
  • Koong, Mi-Kyoung (Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Cheil General Hospital and Women's Healthcare Center, Kwandong University College of Medicine) ;
  • Kang, Inn-Soo (Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Cheil General Hospital and Women's Healthcare Center, Kwandong University College of Medicine) ;
  • Kim, Hye-Ok (Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Cheil General Hospital and Women's Healthcare Center, Kwandong University College of Medicine)
  • 투고 : 2011.11.17
  • 심사 : 2011.12.30
  • 발행 : 2011.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objective: To evaluate the ability of serum anti-M$\ddot{u}$llerian hormone (AMH), FSH, and age to clinically predict ovarian response to controlled ovarian hyperstimulation (COH) in IVF patients with endometriosis. Methods: We evaluated 91 COH cycles, including 43 cycles with endometriosis (group I) and 48 cycles with male factor infertility (group II) from January to December, 2010. Patients were classified into study groups based on their surgical history of endometriosis-group Ia (without surgical history, n=16), group Ib (with a surgical history, n=27). Results: The mean age was not significantly different between group I and group II. However, AMH and FSH were significantly different between group I and group II ($1.9{\pm}1.9$ ng/mL vs. $4.1{\pm}2.9$ ng/mL, $p$ <0.01; $13.1{\pm}7.2$ mIU/mL vs. $8.6{\pm}3.3$ mIU/mL, $p$ <0.01). Furthermore, the number of retrieved oocytes and the number of matured oocytes were significantly lower in group I than in group II. In group II, AMH and FSH as well as age were significant predictors of retrieved oocytes on univariate analysis. Only the serum AMH level was a significant predictor of poor ovarian response in women with endometriosis. Conclusion: Serum AMH may be a better predictor of the ovarian response of COH in patients with endometriosis than basal FSH or age. AMH level can be considered a useful clinical predictor of poor ovarian response in endometriosis patients.

키워드

참고문헌

  1. Kennedy S, Bergqvist A, Chapron C, D'Hooghe T, Dunselman G, Greb R, et al. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod 2005;20:2698-704. https://doi.org/10.1093/humrep/dei135
  2. Giudice LC, Kao LC. Endometriosis. Lancet 2004;364:1789-99. https://doi.org/10.1016/S0140-6736(04)17403-5
  3. Ozkan S, Murk W, Arici A. Endometriosis and infertility: epidemiology and evidence-based treatments. Ann N Y Acad Sci 2008;1127:92-100. https://doi.org/10.1196/annals.1434.007
  4. Mahutte NG, Arici A. Endometriosis and assisted reproductive technologies: are outcomes affected? Curr Opin Obstet Gynecol 2001;13:275-9. https://doi.org/10.1097/00001703-200106000-00005
  5. Kim HO, Park CW, Song IO, Koong MK. IVF/ICSI outcomes of women with minimal to mild endometriosis associated infertility and unexplained infertility. Korean J Obstet Gynecol 2007;50:322-8.
  6. Matalliotakis IM, Cakmak H, Mahutte N, Fragouli Y, Arici A, Sakkas D. Women with advanced-stage endometriosis and previous surgery respond less well to gonadotropin stimulation, but have similar IVF implantation and delivery rates compared with women with tubal factor infertility. Fertil Steril 2007;88:1568-72. https://doi.org/10.1016/j.fertnstert.2007.01.037
  7. Barnhart K, Dunsmoor-Su R, Coutifaris C. Effect of endometriosis on in vitro fertilization. Fertil Steril 2002;77:1148-55. https://doi.org/10.1016/S0015-0282(02)03112-6
  8. Hock DL, Sharafi K, Dagostino L, Kemmann E, Seifer DB. Contribution of diminished ovarian reserve to hypofertility associated with endometriosis. J Reprod Med 2001;46:7-10.
  9. Almog B, Shehata F, Suissa S, Holzer H, Shalom-Paz E, La Marca A, et al. Age-related normograms of serum antimullerian hormone levels in a population of infertile women: a multicenter study. Fertil Steril 2011;95:2359-63. https://doi.org/10.1016/j.fertnstert.2011.02.057
  10. La Marca A, Sighinolfi G, Giulini S, Traglia M, Argento C, Sala C, et al. Normal serum concentrations of anti-Mullerian hormone in women with regular menstrual cycles. Reprod Biomed Online 2010;21:463-9. https://doi.org/10.1016/j.rbmo.2010.05.009
  11. Barad DH, Weghofer A, Gleicher N. Utility of age-specific serum anti-Mullerian hormone concentrations. Reprod Biomed Online 2011;22:284-91. https://doi.org/10.1016/j.rbmo.2010.12.002
  12. Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome NP, Visser JA, et al. Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod 2004;10:77-83. https://doi.org/10.1093/molehr/gah015
  13. van Rooij IA, Broekmans FJ, te Velde ER, Fauser BC, Bancsi LF, de Jong FH, et al. Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve. Hum Reprod 2002;17:3065-71. https://doi.org/10.1093/humrep/17.12.3065
  14. Yoo JH, Kim HO, Cha SW, Park CW, Yang KM, Song IO, et al. Age specific serum anti-Mullerian hormone levels in 1,298 Korean women with regular menstruation. Clin Exp Reprod Med 2011;38:93-7. https://doi.org/10.5653/cerm.2011.38.2.93
  15. Lekamge DN, Barry M, Kolo M, Lane M, Gilchrist RB, Tremellen KP. Anti-Mullerian hormone as a predictor of IVF outcome. Reprod Biomed Online 2007;14:602-10. https://doi.org/10.1016/S1472-6483(10)61053-X
  16. Nelson SM, Yates RW, Lyall H, Jamieson M, Traynor I, Gaudoin M, et al. Anti-Mullerian hormone-based approach to controlled ovarian stimulation for assisted conception. Hum Reprod 2009;24:867-75.
  17. Choi MH, Yoo JH, Kim HO, Cha SH, Park CW, Yang KM, et al. Serum anti-Mullerian hormone levels as a predictor of the ovarian response and IVF outcomes. Clin Exp Reprod Med 2011;38:153-8. https://doi.org/10.5653/cerm.2011.38.3.153
  18. Lemos NA, Arbo E, Scalco R, Weiler E, Rosa V, Cunha-Filho JS. Decreased anti-Mullerian hormone and altered ovarian follicular cohort in infertile patients with mild/minimal endometriosis. Fertil Steril 2008;89:1064-8. https://doi.org/10.1016/j.fertnstert.2007.04.048
  19. Knauff EA, Eijkemans MJ, Lambalk CB, ten Kate-Booij MJ, Hoek A, Beerendonk CC, et al. Anti-Mullerian hormone, inhibin B, and antral follicle count in young women with ovarian failure. J Clin Endocrinol Metab 2009;94:786-92. https://doi.org/10.1210/jc.2008-1818
  20. Falconer H, Sundqvist J, Gemzell-Danielsson K, von Schoultz B, D'Hooghe TM, Fried G. IVF outcome in women with endometriosis in relation to tumour necrosis factor and anti-Mullerian hormone. Reprod Biomed Online 2009;18:582-8. https://doi.org/10.1016/S1472-6483(10)60138-1
  21. La Marca A, Pati M, Orvieto R, Stabile G, Carducci Artenisio A, Volpe A. Serum anti-mullerian hormone levels in women with secondary amenorrhea. Fertil Steril 2006;85:1547-9. https://doi.org/10.1016/j.fertnstert.2005.10.057

피인용 문헌

  1. Ovarian endometrioma: guidelines for selection of cases for surgical treatment or expectant management vol.8, pp.1, 2013, https://doi.org/10.1586/eog.12.75
  2. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice vol.20, pp.1, 2011, https://doi.org/10.1093/humupd/dmt037
  3. Ovarian reserve markers and assisted reproductive technique (ART) outcomes in women with advanced endometriosis vol.12, pp.None, 2011, https://doi.org/10.1186/1477-7827-12-120
  4. Anti-Mullerian hormone trend evaluation after laparoscopic surgery of monolateral endometrioma using a new dual wavelengths laser system (DWLS) for hemostasis vol.32, pp.1, 2016, https://doi.org/10.3109/09513590.2015.1068754
  5. Endometriosis and in vitro fertilisation vol.16, pp.2, 2018, https://doi.org/10.3892/etm.2018.6307
  6. Improvement and effect of stress responses and ovarian reserve function in patients with ovarian cysts after laparoscopic surgery vol.47, pp.7, 2019, https://doi.org/10.1177/0300060519851333